- Home
- LION vs AKRO Comparison
LION vs AKRO Comparison
Compare LION & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LION
- AKRO
- Stock Information
- Founded
- LION 1997
- AKRO 2017
- Country
- LION United States
- AKRO United States
- Employees
- LION N/A
- AKRO N/A
- Industry
- LION Movies/Entertainment
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- LION Consumer Discretionary
- AKRO Health Care
- Exchange
- LION Nasdaq
- AKRO Nasdaq
- Market Cap
- LION 1.9B
- AKRO 3.6B
- IPO Year
- LION N/A
- AKRO 2019
- Fundamental
- Price
- LION $7.38
- AKRO $43.46
- Analyst Decision
- LION Buy
- AKRO Strong Buy
- Analyst Count
- LION 9
- AKRO 8
- Target Price
- LION $8.88
- AKRO $80.38
- AVG Volume (30 Days)
- LION 2.5M
- AKRO 945.4K
- Earning Date
- LION 11-06-2025
- AKRO 11-07-2025
- Dividend Yield
- LION N/A
- AKRO N/A
- EPS Growth
- LION N/A
- AKRO N/A
- EPS
- LION N/A
- AKRO N/A
- Revenue
- LION $3,986,900,000.00
- AKRO N/A
- Revenue This Year
- LION N/A
- AKRO N/A
- Revenue Next Year
- LION $16.90
- AKRO N/A
- P/E Ratio
- LION N/A
- AKRO N/A
- Revenue Growth
- LION 10.89
- AKRO N/A
- 52 Week Low
- LION $5.55
- AKRO $21.34
- 52 Week High
- LION $8.50
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- LION 65.64
- AKRO 36.83
- Support Level
- LION $6.10
- AKRO $42.56
- Resistance Level
- LION $7.69
- AKRO $46.18
- Average True Range (ATR)
- LION 0.33
- AKRO 1.80
- MACD
- LION 0.12
- AKRO -0.19
- Stochastic Oscillator
- LION 80.19
- AKRO 13.42
About LION Lionsgate Studios Corp. Common Shares
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.